Neutralising Residual Complement C5 Activity: Synergistic Potential of Orthogonal Epitope‐Targeting Anti‐C5 Agents
European Journal of Immunology · 2026-11 · 56 (11)
DOI: 10.1002/eji.70326 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, online erschienen am 16.11.2026. Verfasst von Hiba Ghaboosh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, University of Ulm Medical Centre, Ulm, Germany. Hauptthemen laut MEDLINE: Complement C5, Epitopes, Complement Inactivating Agents. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Academic Exchange Service, Deutsche Forschungsgemeinschaft, Deutscher Akademischer Austauschdienst.
Abstract (Originalsprache)
Complement protein C5 activation initiates the lytic and inflammatory terminal pathway, making C5 a prime therapeutic target. Clinically approved or trial‐stage C5 inhibitors (Eculizumab, Ravulizumab, Crovalimab, and OmCI) target distinct epitopes on C5. Here, we compare their binding and inhibitory potency in vitro. Individually, all agents showed substantial residual lytic C5 activity in alternative pathway (AP) haemolysis assays, though complete inhibition was achieved in classical pathway settings. Notably, Ravulizumab was slightly less effective than Eculizumab in preventing haemolysis, potentially due to its faster off‐rate from C5, as observed by surface plasmon resonance. To address residual AP haemolysis, we tested all combinations of orthogonal epitope‐targeting anti‐C5 agents. Every combination fully inhibited lytic complement activity. Additionally, all monoclonal anti‐C5 antibodies tested here bound stably to C5 activation fragments (C5b6 and sC5b‐9), comparable to their interactions with C5. Residual C5 activity during strong complement activation appears to be a class effect of single‐agent C5 inhibition, but it can be overcome by combining inhibitors targeting orthogonal C5 epitopes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, University of Ulm Medical Centre, Ulm, Germany.
- Institute of Transfusion Medicine, University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, University Hospital of Ulm and German Red Cross Blood Service Baden-Württemberg - Hessen, Ulm,…
Förderung
- German Academic Exchange Service
- Deutsche Forschungsgemeinschaft
- Deutscher Akademischer Austauschdienst
Zitieren
APA
Ghaboosh, H., Kaufmann, V., Sichau, J., Höchsmann, B., Schrezenmeier, H., & Schmidt, C. Q. (2026). Neutralising Residual Complement C5 Activity: Synergistic Potential of Orthogonal Epitope‐Targeting Anti‐C5 Agents. European Journal of Immunology, 56(11). https://doi.org/10.1002/eji.70326
Vancouver
Ghaboosh H, Kaufmann V, Sichau J, Höchsmann B, Schrezenmeier H, Schmidt CQ. Neutralising Residual Complement C5 Activity: Synergistic Potential of Orthogonal Epitope‐Targeting Anti‐C5 Agents. European Journal of Immunology. 2026;56(11). doi:10.1002/eji.70326
BibTeX
@article{Ghaboosh2026,
author = {Ghaboosh, Hiba and Kaufmann, Vanessa and Sichau, Jannik and Höchsmann, Britta and Schrezenmeier, Hubert and Schmidt, Christoph Q},
title = {Neutralising Residual Complement C5 Activity: Synergistic Potential of Orthogonal Epitope‐Targeting Anti‐C5 Agents},
journal = {European Journal of Immunology},
year = {2026},
volume = {56},
number = {11},
doi = {10.1002/eji.70326}
}
EUVIMED